Case Report: Presumed digynic triploidy (69,XXX) with a low-risk NIPT result and fetal-placental chromosomal discordance presenting as severe fetal growth restriction in the third trimester
Year: 2026
Type: article
Study design: Case Report
Abstract: Background Triploidy is a generally lethal chromosomal abnormality with only rare livebirths and no established long-term survival. Although non-invasive prenatal testing (NIPT) is highly effective for common trisomies, its reliability for detecting triploidy is constrained-resulting in delays in prenatal diagnosis. Case presentation A 30-year-old woman presented with progressive severe fetal growth restriction (FGR) and multiple anomalies (bilateral clenched hands, wrist drop, small stomach, right aortic arch with aberrant left subclavian artery) from the second trimester. NIPT at 19 weeks reported low risk for trisomies 21, 18, and 13, with a fetal cell-free DNA (cfDNA) fraction of 3.2%, which was below the laboratory-specific 4% threshold for the BGISEQ-500 assay used in this case. Triploidy was not within the validated reportable scope of this assay. Amniocentesis at 28 weeks with chromosomal microarray analysis (CMA) revealed 69,XXX triploidy. Parental peripheral blood STR analysis confirmed a maternal (digynic) origin. Post-termination, CMA of two independent placental samples showed a 46,XX profile; no triploid cell line was detected in the two sampled sites. These findings indicate fetal-placental chromosomal discordance rather than definitively confirmed confined placental mosaicism. Conclusion This case highlights a multi-layered diagnostic vulnerability: counting-based algorithmic limitations for genome-wide triploidy, low fetal fraction associated with digynic triploidy, and possible biological masking by diploid placental tissue. A low-risk NIPT result for common trisomies does not exclude triploidy, especially when severe FGR and structural anomalies are present. In such high-risk scenarios, clinical management should be guided by fetal imaging rather than cfDNA results, and amniocentesis remains the preferred diagnostic test for definitive fetal karyotyping.
Source: Frontiers in Medicine
Authors: Lei Li, Yangyang Chen
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7225875124
